Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Brochures & Literature

 

 

View Channel

 

Conferences | Events

Agilent Technologies Announces Twist Bioscience Agrees to Pay $22.5 Million Settlement in IP Litigation

publication date: Feb 17, 2020
 | 
author/source: Agilent Technologies

agilent-technologies-announces-twist-bioscience-agrees


Agilent Technologies Inc. has announced it has reached an agreement with Twist Bioscience under which Twist has agreed to pay Agilent a sum of $22.5 million to settle Agilent’s claims against Twist, as well as current and former Twist employees Emily Leproust, Siyuan Chen, and Solange Glaize.

The claims included trade secret misappropriation claims against Twist, Dr. Leproust, Dr. Chen and Ms. Glaize, breach of contract claims against Dr. Leproust, Dr. Chen and Ms. Glaize, and breach of duty of loyalty claims against Dr. Leproust. The settlement agreement provides a license to Twist for discrete aspects of Agilent’s oligo-synthesis technology and successfully resolves all outstanding litigation between all parties.

“This settlement vindicates Agilent’s deep commitment to protecting our intellectual property,” said Simone Schiller, associate vice president and managing counsel for Global Litigation at Agilent. “Agilent is in the business of innovation and driving technology forward the right way is central to what we do. From the outset, our goal has been to protect our proprietary technology and the hard work of the many scientists and engineers who built it. This settlement accomplishes that.”

The promise and potential applications of synthetic biology are world-changing, from manufacturing chemicals and biofuels to providing breakthroughs in detecting and treating diseases. Agilent is extremely proud of its R&D track record, and of the important contributions the company is making through its pioneering oligo-synthesis technology. This leading technology enables Agilent customers to make new and wide-ranging scientific discoveries, including groundbreaking research and development aimed at improving health and saving lives. Agilent welcomes competition on its merits and looks forward to continuing to drive innovation in this exciting new area. Agilent’s goal is, and remains, the advancement of science.

 

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide.

 

more news from Agilent



If you have not logged into the website then please enter your details below.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners